OBJECTIVES:  MM- and MM-treatment induced peripheral neuropathy (TIPN) impairs quality of life and imposes function limitations in patients. This study examined medical costs attributable to TIPN in MM patients in the US. METHODS:  Adult patients diagnosed with MM (ICD-9-CM code 203.0x) and ≥1 MM treatment between 7/1/2006 - 3/31/2015 were extracted from MarketScan claims databases. Patients had ≥12-month continuous enrollment (baseline) before initiation of first MM treatment (index date), and were followed for ≥3 months until inpatient death or end of data. “TIPN” was identified by ICD-9-CM claim codes indicating PN post index (8-270 days) and no PN claims during baseline and ≤7 days post-index. Patients without a PN diagnosis anytime during the study period served as controls. Controls were propensity score matched to TIPN patients. Medical costs per patient per month (PPPM, in 2015 $) in the post-index period are reported. RESULTS:  A total of 10,716 patients met study criteria and 10.7% had TIPN; 1120 TIPN and 3265 controls were matched. Baseline characteristics in the two groups were similar (mean age: 64; male: 61-62%; renal disease: 24-25%; mean follow up: 22-24 months). PPPM total costs were significantly higher by $1059 (p=0.018) for TIPN patients (TIPN: mean costs $15,978 (SD $13,437); controls: $14,919 (SD $12,767)), which were driven by inpatient costs ($475 higher) and outpatient medical costs ($501 higher). Total costs of TIPN patients were $2,456 higher during the first quarter post index and $3,536 higher during the second quarter (p<0.001). Costs were not significantly different between TIPN patients and controls during the third and fourth quarter post index. CONCLUSIONS:  TIPN is prevalent in patients with MM; it adds to the complexity and cost of MM treatment. There is an unmet need for effective novel treatments that do not add to the economic burden associated with TIPN.